Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtech Worried After UK HTA Body Moots Pharma Guidance Fees

Executive Summary

The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.

You may also be interested in...

Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs

UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.

As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform

A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.

UK Life Sciences Vows To Maximize Post-Brexit Opportunities

The UK is “open for business” as far as the life-sciences sector is concerned, and those with ministerial and departmental oversight are promising to work with the realities – still largely unknown – that the country's exit from the EU will bring forth. Such was the tone of UK Office for Life Sciences’ director Nicole Mather, speaking to health-care industry delegates Sept. 15 in London.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts